1. Co‐administration of 2’3’-cGAMP STING activator and CpG-C adjuvants with a mutated form of HPV 16 E7 protein leads to tumor growth inhibition in the mouse model
   Fariba Dorostkar et al, 2021, Infectious Agents and Cancer CrossRef
2. Genetic variability of human papillomavirus type 39 based on E6, E7 and L1 genes in Southwest China
   Jiaoyu He et al, 2021, Virology Journal CrossRef
3. Targeted Biological Effect of An Affitoxin Composed of an HPV16E7 Affibody Fused with Granzyme B (ZHPV16E7-GrB) Against Cervical Cancer In vitro and In vivo
   Wenhuan Wang et al, 2021, Current Cancer Drug Targets CrossRef
4. Development of Multiepitope Therapeutic Vaccines Against the Most Prevalent High-Risk Human Papillomaviruses
   Heidar Ali Panahi et al, 2020, Immunotherapy CrossRef
5. Effective Neutralizing Antibody Produced in Mice Directly Immunized with Integrated Pichia pastoris Expressing HPV16L1 Protein
   Zhen Xv et al, 2019, Viral Immunology CrossRef
6. Intranasal Therapeutic Peptide Vaccine Promotes Efficient Induction and Trafficking of Cytotoxic T Cell Response for the Clearance of HPV Vaginal Tumors
   Gloria Sierra et al, 2020, Vaccines CrossRef